Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study

被引：0
作者：
Chao Xu
Xiaoli Xie
Ning Kang
Huiqing Jiang
机构：
[1] The Second Hospital of Hebei Medical University,Department of Gastroenterology
[2] Handan Central Hospital,Department of Gastroenterology
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Locally advanced gastric cancer; Apatinib; Programmed cell death protein 1 inhibitor; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4091 / 4099
页数：8
相关论文
共 50 条
  • [41] Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1alone in locally advanced gastric cancer(RESCUE-GC study): a protocol for a phase Ⅲ randomized controlled trial
    Xiang Hu
    Lin Chen
    Yian Du
    Biao Fan
    Zhaode Bu
    Xin Wang
    Yingjiang Ye
    Zhongtao Zhang
    Gang Xiao
    Fei Li
    Qingsi He
    Guoli Li
    Xian Shen
    Bin Xiong
    Liming Zhu
    Jiwei Liu
    Lian Liu
    Tao Wu
    Jing Zhou
    Jun Zhang
    Gang Zhao
    Xulin Wang
    Pin Liang
    Xinxin Wang
    Yan Zhang
    Xiaojiang Wu
    Ji Zhang
    Xin Ji
    Xianglong Zong
    Tao Fu
    Ziyu Jia
    Jiafu Ji
    ChineseJournalofCancerResearch, 2017, 29 (02) : 144 - 148
  • [42] Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer
    Takahiro Tsushima
    Shuichi Hironaka
    Narikazu Boku
    Nozomu Machida
    Kentaro Yamazaki
    Hirofumi Yasui
    Akira Fukutomi
    Akiko Todaka
    Hiroya Taniguchi
    Yusuke Onozawa
    Keisei Taku
    International Journal of Clinical Oncology, 2013, 18 : 10 - 16
  • [43] Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer
    Tsushima, Takahiro
    Hironaka, Shuichi
    Boku, Narikazu
    Machida, Nozomu
    Yamazaki, Kentaro
    Yasui, Hirofumi
    Fukutomi, Akira
    Todaka, Akiko
    Taniguchi, Hiroya
    Onozawa, Yusuke
    Taku, Keisei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (01) : 10 - 16
  • [44] Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study
    Qu Liu
    Guodong Zhao
    Xiuping Zhang
    Nan Jiang
    Zhiming Zhao
    Yang Wang
    Shuai Xu
    Lin Zhu
    Wan Yee Lau
    Guanghai Dai
    Rong Liu
    Langenbeck's Archives of Surgery, 2022, 407 : 633 - 643
  • [45] Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study
    Liu, Qu
    Zhao, Guodong
    Zhang, Xiuping
    Jiang, Nan
    Zhao, Zhiming
    Wang, Yang
    Xu, Shuai
    Zhu, Lin
    Lau, Wan Yee
    Dai, Guanghai
    Liu, Rong
    LANGENBECKS ARCHIVES OF SURGERY, 2022, 407 (02) : 633 - 643
  • [46] PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer
    Chen, Hao
    Jiang, Tao
    Lin, Fangyu
    Guan, Hongdan
    Zheng, Jianwei
    Liu, Qing
    Du, Bing
    Huang, Yeyuan
    Lin, Xiaoyan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [47] Efficacy and optimal combination timing of chemotherapy combined with PD-1 inhibitor in advanced cervical cancer: a multicenter retrospective cohort study
    Ma, Yi-Ming
    Cheng, Shu-Xia
    Zhang, Ming-Chuan
    Zhang, Hui-Ying
    Gu, Jun-Jiao
    Zhao, Pan-Pan
    Ge, Hong
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (20)
  • [48] Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)
    Yuehong Cui
    Yiyi Yu
    Song Zheng
    Jie’er Ying
    Yi’an Du
    Yan Wang
    Xuefei Wang
    Zhenbin Shen
    Fenglin Liu
    Minzhi Lv
    Yihong Sun
    Tianshu Liu
    BMC Cancer, 23
  • [49] Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)
    Cui, Yuehong
    Yu, Yiyi
    Zheng, Song
    Ying, Jie'er
    Du, Yi'an
    Wang, Yan
    Wang, Xuefei
    Shen, Zhenbin
    Liu, Fenglin
    Lv, Minzhi
    Sun, Yihong
    Liu, Tianshu
    BMC CANCER, 2023, 23 (01)
  • [50] HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study
    Chang, Xu
    Li, Xinge
    Sun, Peng
    Li, Zhenfeng
    Sun, Pengfei
    Ning, Shangkun
    BMC CANCER, 2024, 24 (01)
12345